- About us
- Clinical trials
- News & Publications
SOTIO to Present Results from Phase II Clinical Trial of 1st-Line Ovarian Cancer Treatment in Oral Presentation at ASCO 2018 Annual Meeting
SOTIO, a biotechnology company owned by the PPF Group, today announces the presentation of new promising clinical data from its ovarian and lung cancer clinical trials evaluating DCVAC, an active cellular immunotherapy product. Data will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from 1-5 June, in Chicago, IL, United States.
SOTIO Receives Positive Opinion for Orphan Drug Designation for DCVAC/OvCa from European Medicines Agency (EMA)
SOTIO, a biotechnology company owned by the PPF Group, today announces that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending orphan medicinal product (orphan drug) designation for DCVAC/OvCa for the treatment of patients with ovarian cancer. The EMA’s positive opinion follows a similar decision issued previously by the U.S. Food and Drug Administration (FDA).
Radek Špíšek to become new CEO of SOTIO
SOTIO, a biotechnology company belonging to the PPF Group, announces today the appointment of Professor Radek Špíšek as Chief Executive Officer. Effective from March 1, 2018, he will replace the current CEO, Ladislav Bartoníček, who will remain active within SOTIO’s top management and will replace Radek Špíšek on the company’s Supervisory Board. The appointment of Radek Špíšek as the CEO will ensure continuity in the company’s management and strategic goals.